⭐ Home≡ MenuNews

Canavan Disease Information

  • Publish Date : 2009/04/01 - (Rev. 2019/08/12)
  • Author : Disabled World
  • Contact : www.disabled-world.com

Synopsis:

Canavan disease is a severe progressive inherited genetic disorder of the central nervous system.

Canavan disease is caused by mutations in the gene for an enzyme called aspartoacylase.

Although Canavan disease may occur in any ethnic group, it is more frequent among Ashkenazi Jews from eastern Poland, Lithuania, and western Russia, and among Saudi Arabians.

Main Document

Canavan disease alternate names include: Aminoacylase-2 (ACY2) Deficiency, Aspartoacylase (ASPA) Deficiency, Canavan's Leukodystrophy, Spongy Degeneration of the Central Nervous System or Neuroaxis, Van Bogaert-Bertrand Syndrome.

Canavan disease (CD) is a severe progressive inherited (genetic) disorder of the central nervous system (CNS). It is one of the most common cerebral degenerative diseases of infancy, is a gene-linked, neurological birth disorder in which the white matter of the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces.

Canavan disease is one of a group of genetic disorders known as the leukodystrophies. These diseases cause imperfect growth or development of the myelin sheath, the fatty covering that acts as an insulator around nerve fibers in the brain. Myelin, which lends its color to the "white matter" of the brain, is a complex substance made up of at least ten different chemicals. Each of the leukodystrophies affects one (and only one) of these substances.

Canavan disease is caused by mutations in the gene for an enzyme called aspartoacylase.

Symptoms of Canavan disease, which appear in early infancy and progress rapidly, may include mental retardation, loss of previously acquired motor skills, feeding difficulties, abnormal muscle tone (floppiness or stiffness), and an abnormally large, poorly controlled head. Paralysis, blindness, or hearing loss may also occur.

Children are characteristically quiet and apathetic.

Although Canavan disease may occur in any ethnic group, it is more frequent among Ashkenazi Jews from eastern Poland, Lithuania, and western Russia, and among Saudi Arabians.

Clinical findings leading up to the diagnosis would include:

  • Physical findings including the triad of hypotonia (low muscle tone), macrocephaly (abnormally large head) and head lag in an infant age three to five months of age or older.
  • CT and MRI abnormalities of the cerebral white matter (relatively spared cerebellum and brain stem white matter).
  • Urine gas chromatography-mass spectrometry (GC-MS) finding of elevated N-acetylaspartic acid (NAA).

The test to confirm diagnosis is a full gene sequence analysis of ASPA. Gross deletion/duplication analysis of the entire ASPA gene is performed to detect known and potential novel gross deletions.

Canavan disease causes brain tissue atrophy cystic cavities resulting in enlargement of the brain and head size. There is no cure, nor is there a standard course of treatment. Treatment is symptomatic and supportive. The prognosis for Canavan disease is poor. Death usually occurs before age 4.

Similar Documents

Cite:





• Important Disclaimer: Information provided on disabled-world.com is for general informational and educational purposes only, it is not offered as and does not constitute medical advice. In no way are any of the materials presented meant to be a substitute for professional medical care or attention by a qualified practitioner, nor should they be construed as such. Any third party offering or advertising on disabled-world.com does not constitute an endorsement by Disabled World. All trademarks(TM) and registered(R) trademarks are the property of their respective owners. Please report outdated or inaccurate information to us.